SCHEMBL23833436

SCHEMBL23833436

COc1ncc(NC(=O)c2ccc3nc(C)ccc3c2)cc1S(=O)(=O)Nc1ccc(Cl)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 7/20 0.46
KMT2A Q03164 7/20 0.46
MAPT P10636 5/20 0.45
HTT P42858 4/20 0.45
IDH1 O75874 5/20 0.44
LMNA P02545 5/20 0.44
NPC1 O15118 3/20 0.44
RAB9A P51151 3/20 0.44
KDM4E B2RXH2 2/20 0.44
ALDH1A1 P00352 3/20 0.43
SMN1; SMN2 Q16637 3/20 0.43
MITF O75030 1/20 0.43
MAPK1 P28482 1/20 0.43
POLB P06746 1/20 0.43
ALPL P05186 2/20 0.42
ALOX12 P18054 1/20 0.42
HPGD P15428 2/20 0.42
NPSR1 Q6W5P4 1/20 0.42
NAMPT P43490 1/20 0.41
EGFR P00533 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30151099 1.00 MEN1 (0.46) MEN1KMT2AMAPTHTTIDH1
SCHEMBL23840308 0.94 MEN1 (0.46) MEN1KMT2AMAPTHTTIDH1
SCHEMBL23833405 0.85 MAPT (0.53) MEN1KMT2AMAPTHTTIDH1
SCHEMBL23833409 0.81 SMN1; SMN2 (0.53) MEN1KMT2AMAPTHTTIDH1
SCHEMBL30151054 0.81 SMN1; SMN2 (0.53) MEN1KMT2AMAPTHTTIDH1
SCHEMBL23833492 0.76 KDM4E (0.59) MEN1KMT2AMAPTHTTIDH1
SCHEMBL23833480 0.76 GPR27 (0.48) MEN1KMT2AMAPTHTTIDH1
SCHEMBL30151063 0.76 GPR27 (0.48) MEN1KMT2AMAPTHTTIDH1
SCHEMBL23840608 0.76 IDH1 (0.42) MEN1KMT2AMAPTHTTIDH1
SCHEMBL23846587 0.74 IDH1 (0.53) MEN1KMT2AMAPTIDH1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230159509-A1 PYRIDINESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF AMATHUS THERAPEUTICS, INC. (US) 2023-05-25 US disclosed
EP-4121030-A1 PYRIDINESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF Amathus Therapeutics, Inc. (US) 2023-01-25 EP disclosed
WO-2021188907-A1 PYRIDINESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF AMATHUS THERAPEUTICS, INC. (US) 2021-09-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230159509-A1 PYRIDINESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF TRAP1, PINK1, PPM1D MEN1 3610/4885KMT2A 4866/4885MAPT 66/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.